Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (Nasdaq: QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Quantum-Si’s benchtop protein sequencing platform, chemistry kits, and data analysis tools are evolving over time.
Recent Quantum-Si news has highlighted product launches such as the V4 Sequencing Kit, which the company reports improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The company has also announced a Version 3 Library Preparation Kit designed for lower protein input and detection of low-abundance proteins, along with data analysis enhancements that unlock detection of additional amino acids and improve peptide alignment and protein inference.
Investors and researchers can use this page to track updates on Quantum-Si’s Proteus platform development, including prototype sequencing milestones, technology roadmap disclosures, and plans related to amino acid coverage, controlled cleavage chemistry, and post-translational modification methods. Financial news items, such as quarterly earnings releases, capital raising transactions, and lease or other material agreements disclosed via Form 8-K, also appear in this feed.
In addition, the news stream captures corporate governance and human capital updates, including inducement grants under the company’s 2023 Inducement Equity Incentive Plan, investor conference participation, and Investor & Analyst Day events. Bookmark this page to review Quantum-Si’s official press releases and regulatory news in one place, with a focus on developments that shape the company’s proteomics technology, commercialization efforts, and capital markets activity.
Quantum-Si (Nasdaq: QSI) will report first quarter 2026 financial results on May 7, 2026. A conference call and live webcast with CEO Jeff Hawkins and CFO Jeff Keyes will occur the same day at 4:30 PM ET. An archived webcast will be available after the event.
Investors can listen via the Investors section of the company website or register to receive a dial-in number and personalized PIN to participate.
Quantum-Si (Nasdaq: QSI) announced two customer posters at the American Association of Cancer Research (AACR) annual meeting, April 17-22, 2026 in San Diego.
Poster 2421 (April 20) by Nigel O’Neil, PhD, covers combining deep mutational scanning with benchtop protein sequencing for DNA repair inhibitors. Poster 7650 (April 22) by Gloria Sheynkman, PhD, shows high-resolution PTM detection using single-molecule protein sequencing and its potential to add proteoform characterization to biomarker studies. Management noted ongoing customer pre-prints and momentum toward the planned Proteus launch.
Quantum-Si (Nasdaq: QSI) announced a new manuscript (pre-print, April 14, 2026) showing single-molecule protein sequencing helped identify hybrid human–yeast cohesin complexes relevant to cancer biology. The study used QSI technology to directly demonstrate physical assembly of human and yeast cohesins, a finding that could inform therapeutic discovery.
Quantum-Si (Nasdaq: QSI) granted 61,439 restricted stock units (RSUs) as inducement awards to new employees under its 2023 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on June 20, 2027, with the remainder vesting in 12 equal quarterly installments, subject to continued employment and plan terms.
Quantum-Si (Nasdaq: QSI) completed sequencing of multiple customer samples on a Proteus prototype, testing samples on both Platinum Pro and the Proteus prototype.
According to the company, the Proteus prototype with a developmental sequencing kit delivered improved amino acid coverage, longer read lengths, more peptides identified and greater sequencing output versus Platinum Pro.
Quantum-Si (NASDAQ: QSI) announced a multi-city roadshow to build awareness for its Proteus protein sequencing platform and develop a customer funnel ahead of commercial launch.
First events are in Seattle on April 7, 2026, Washington, D.C. on April 30, 2026, and Houston on May 5, 2026; additional U.S. and European dates will follow.
Quantum-Si (Nasdaq: QSI) granted 88,781 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on March 20, 2027, with the remainder vesting in 12 equal quarterly installments, subject to continued employment and plan terms.
Quantum-Si (Nasdaq: QSI) reported fourth quarter 2025 revenue of $0.5M and full-year 2025 revenue of $2.4M, with gross margins of 27% (Q4) and 47% (full year).
The company announced a Proteus list price of $425,000, reiterated a year-end 2026 launch target, and provided 2026 guidance: revenue ~$1.0M, adjusted operating expenses ≤$98.0M, and total cash usage ≤$93.0M. Cash and investments totaled $215.8M as of December 31, 2025.
Quantum-Si (Nasdaq: QSI) announced that its Compensation Committee granted 52,296 restricted stock units (RSUs) to new employees under the company’s 2023 Inducement Equity Incentive Plan.
The RSUs vest 25% on March 20, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment and plan terms.
Quantum-Si (Nasdaq: QSI) will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. Management will host a conference call and live webcast at 4:30 PM ET the same day to discuss results and provide a business update.
Webcast access and dial-in registration details are available on the company’s Investors section; an archived replay will be posted after the event.